ROIV ▲ +1.6% - Roivant Sciences Ltd. $ROIV ROIVW - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Roivant Sciences shares rose 1.6% following the company's announcement that the FDA has approved LISRAYA™ (brepocitinib) for treating dermatomyositis in adults. The approval represents a significant milestone for the company, as LISRAYA is now available for commercial distribution in the U.S. market, potentially opening a new revenue stream for the biopharmaceutical company. 27-AUG-2026 03:29 PM ET